Family Medicine · Preston, ID
NPI
1801909122
Since 2006
Specialty
Family Medicine
Code 207Q00000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
41 North 1 East
Preston, ID, 83263
Phone (208) 852-3851
Groups this clinician bills Medicare through
Medicare paid, 2024
$168K
3,136 services
Medicare patients, 2024
581
Average age 75
Drug cost, 2024
$1.3M
20,288 prescriptions
Company payments, 2025
$85.17
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David B Beckstead was code 99213 (office e&m - established), 1,389 times for 458 patients. In total David B Beckstead billed 3,136 services in 48 codes, and Medicare paid $168K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 1,389 | 458 | $47.27 | $66K |
| 99214 Office E&M - Established | Office | 406 | 210 | $68.75 | $28K |
| 99232 Hospital E&M - Subsequent | Facility | 247 | 63 | $52.40 | $13K |
| 99215 Office E&M - Established | Office | 244 | 124 | $81.08 | $20K |
| G0008 Administration of influenza virus vaccine | Office | 133 | 131 | $29.88 | $3,974 |
| 90658 Vaccine Product | Office | 131 | 131 | $21.42 | $2,806 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 114 | 114 | $108.62 | $12K |
| 99222 Hospital E&M - Initial | Facility | 61 | 54 | $86.56 | $5,280 |
| 99239 Hospital Discharge Management | Facility | 60 | 52 | $76.26 | $4,576 |
| 17000 Destruction Skin Lesion | Office | 37 | 30 | $34.41 | $1,273 |
| J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 35 | 16 | $4.84 | $170 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 32 | 26 | $33.37 | $1,068 |
| 96372 Injection Administration | Office | 26 | 15 | $9.18 | $239 |
| 99238 Hospital Discharge Management | Facility | 16 | 16 | $50.33 | $805 |
By year: 2022 $222K for 4,347 services; 2023 $180K for 3,423 services; 2024 $168K for 3,136 services.
Medicare prescription drug claims, 2024
In 2024, the drug David B Beckstead prescribed most often to Medicare patients was Levothyroxine Sodium, with 873 prescriptions and refills. In total David B Beckstead wrote 20,288 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 873 | 2,053 | 191 | $13K |
| Omeprazole Generic | 745 | 1,706 | 187 | $12K |
| Losartan Potassium Generic | 744 | 1,854 | 186 | $11K |
| Atorvastatin Calcium Generic | 530 | 1,383 | 145 | $7,456 |
| Gabapentin Generic | 506 | 869 | 106 | $13K |
| Metoprolol Succinate Generic | 445 | 996 | 120 | $10K |
| Metformin Hcl Generic | 403 | 925 | 101 | $7,806 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 401 | 401 | 83 | $14K |
| Tramadol Hcl Generic | 387 | 387 | 85 | $5,658 |
| Potassium Chloride Generic | 374 | 676 | 82 | $11K |
| Furosemide Generic | 372 | 653 | 86 | $2,791 |
| Zolpidem Tartrate Generic | 357 | 359 | 49 | $1,554 |
| Amlodipine Besylate Generic | 346 | 799 | 92 | $3,530 |
| Azithromycin Generic | 331 | 331 | 255 | $1,305 |
| Eliquis Apixaban | 329 | 433 | 52 | $235K |
Brand drugs: 1,956 claims; generic drugs: 18,315 claims; opioid claims: 1,014.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David B Beckstead $85.17 ($85.17 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbvie Inc. with $52.06.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.